Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study

Study (38,731 new users of GLP-1 receptor agonists matched to new users of dipeptidyl peptidase 4 [DPP-4) inhibitors) found a reduced risk of serious renal events with GLP-1 receptor agonists vs DPP-4 inhibitors (4.8 vs 6.3 events per 1000 person-years, HR 0.76, 95% CI 0.68-0.85)

Diabetes Care